Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | GGT1 | P19440 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL137240 | 1.00 | RNPEP (0.33) | RNPEPALDH1A1GGT1MEN1CYP1A2 | |
| SCHEMBL4080730 | 0.98 | RNPEP (0.34) | RNPEPALDH1A1GGT1MEN1CYP1A2 | |
| SCHEMBL4080725 | 0.98 | RNPEP (0.34) | RNPEPALDH1A1GGT1MEN1CYP1A2 | |
| SCHEMBL28286570 | 0.80 | ALDH1A1 (0.32) | RNPEPALDH1A1 | |
| SCHEMBL137238 | 0.78 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL8631296 | 0.77 | RNPEP (0.35) | RNPEPALDH1A1GGT1MEN1CYP1A2 | |
| SCHEMBL29013093 | 0.77 | RNPEP (0.35) | RNPEPALDH1A1GGT1MEN1CYP1A2 | |
| SCHEMBL162368 | 0.76 | GGT1 (0.52) | RNPEPALDH1A1GGT1MEN1CYP1A2 | |
| SCHEMBL162014 | 0.76 | GGT1 (0.52) | RNPEPALDH1A1GGT1MEN1CYP1A2 | |
| SCHEMBL5614536 | 0.76 | GGT1 (0.52) | RNPEPALDH1A1GGT1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11083685-B2 | Methods for treating scars and aging skin | ALLERGAN, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-10398640-B2 | Methods for treating scars and aging skin | ALLERGAN, INC. | 2019-09-03 | — | — | US | disclosed |
| CN-103717200-B | Phospho-or sulfat-compounds, compositions containing them and topical use thereof | 赛德玛公司 | 2016-08-31 | — | — | CN | disclosed |
| EP-2525774-B1 | NEW LIPO-PHOSPHATED OR LIPO-SULPHATED COMPOUND, COMPOSITIONS COMPRISING IT AND TOPICAL USES THEREOF | SEDERMA SA (FR) | 2016-03-30 | — | — | EP | disclosed |
| US-20160058816-A1 | METHODS FOR TREATING SCARS AND AGING SKIN | ALLERGAN, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160058693-A1 | METHODS FOR TREATING SCARS AND AGING SKIN | ALLERGAN INC (US) | 2016-03-03 | — | — | US | disclosed |
| CN-105311017-A | Compound [alpha]-keto acid composition and preparation method of same | TIANJIN JINYAO GROUP CO LTD | 2016-02-10 | — | — | CN | disclosed |
| CN-105311018-A | Stable compound [alpha]-keto acid tablet composition and preparation method thereof | TIANJIN JINYAO GROUP CO LTD | 2016-02-10 | — | — | CN | disclosed |
| US-9180158-B2 | Methods for treating scars and aging skin | ALLERGAN, INC. | 2015-11-10 | — | — | US | disclosed |
| US-9180157-B2 | Methods for treating scars and aging skin | ALLERGAN, INC. | 2015-11-10 | — | — | US | disclosed |
| CN-103951596-A | Preparation method of medicinal D, L-alpha-hydroxymethionine calcium | HEBEI YIPIN PHARMACEUTICAL CO LTD | 2014-07-30 | — | — | CN | disclosed |
| CN-103951596-A | Preparation method of medicinal D, L-alpha-hydroxymethionine calcium | HEBEI YIPIN PHARMACEUTICAL CO LTD | 2014-07-30 | — | — | CN | disclosed |
| CN-103717200-A | Novel phosphate or sulfate compounds, compositions containing same and topical uses thereof | SEDERMA SA | 2014-04-09 | — | — | CN | disclosed |
| US-20130337088-A1 | METHODS FOR TREATING SCARS AND AGING SKIN | ALLERGAN, INC. | 2013-12-19 | — | — | US | disclosed |
| US-8603498-B2 | Lipo-phosphated or lipo-sulphated compound, compositions comprising it and topical uses thereof | SEDERMA, S.A.S. (FR) | 2013-12-10 | — | — | US | disclosed |
| US-8591961-B2 | Aesthetic treatment of scars and aging skin | ALLERGAN, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20130004439-A1 | Lipo-Phosphated or Lipo-Sulphated Compound, Compositions Comprising It and Topical Uses Thereof | SEDERMA, S.A.S. (FR) | 2013-01-03 | — | — | US | disclosed |
| US-20120058076-A1 | AESTHETIC TREATMENT OF SCARS AND AGING SKIN | ALLERGAN, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20120058167-A1 | METHODS FOR TREATING SCARS AND AGING SKIN | ALLERGAN, INC. | 2012-03-08 | — | — | US | disclosed |
| WO-2011086532-A1 | NEW LIPO-PHOSPHATED OR LIPO-SULPHATED COMPOUND, COMPOSITIONS COMPRISING IT AND TOPICAL USES THEREOF | SEDERMA (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130004439-A1 | Lipo-Phosphated or Lipo-Sulphated Compound, Compositions Comprising It and Topical Uses Thereof | LOXL3, CUTA, LOXL4 | RNPEP 1856/4885ALDH1A1 1329/4885GGT1 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.